2-anilino-4-(1,2-dimethylimidazol-5-yl)pyrimidine

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 2-anilino-4-(1,2-dimethylimidazol-5-yl)pyrimidine
• 英文别名: 4-(2,3-dimethylimidazol-4-yl)-N-phenylpyrimidin-2-amine
• 化学式: C₁₅H₁₅N₅
• 分子量: 265.318
• InChiKey: QMEHPLCOBIOVAP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  20
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.13
• 拓扑面积：
  55.6
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  2-anilino-4-(1,2-dimethylimidazol-5-yl)pyrimidine 在 氯磺酸 、 氯化亚砜 作用下， 反应 3.5h， 生成 C₁₅H₁₄ClN₅O₂S
  参考文献：
  名称：

  Imidazolo-5-YL-2anilino-pyrimidines as agents for the inhibition of the cell proliffration

  摘要：

  该公式化合物（I）：其中R1、R2、R3、R4、R5、R6、p、q和n的定义如下，并描述了其药用盐和体内可水解酯。还描述了它们的制备过程以及它们作为药物的用途，特别是作为用于在温血动物（如人）中产生细胞周期抑制（抗细胞增殖）作用的药物。

  公开号：

  US20040014776A1
• 作为产物：
  描述：

  5-(3-dimethylaminoprop-2-en-1-oyl)-1,2-dimethylimidazole 、 苯基胍碳酸盐 以to give the title compound 113 mg, (26%) as a solid的产率得到2-anilino-4-(1,2-dimethylimidazol-5-yl)pyrimidine
  参考文献：
  名称：

  Imidazolo-5-yl-2-anilino-pyrimidines as agents for the inhibition of the cell proliferation

  摘要：

  式(I)的化合物：其中R1、R2、R3、R4、R5、R6、p、q和n的定义如内部所述，并且所述化合物的药学上可接受的盐和体内可水解的酯被描述。还描述了它们的制备过程以及它们作为药物的用途，特别是作为在温血动物（如人）中产生细胞周期抑制（抗细胞增殖）效应的药物。

  公开号：

  US20060004033A1

文献信息

• [EN] DERIVATIVES OF 4- (IMIDAZOL-5-YL)-2-(4-SULFOANILINO) PYRIMIDINE WITH CDK INHIBITORY ACTIVITY<br/>[FR] DERIVES DE 4- (IMIDAZOL-5-YL)-2-(4-SULFOANILINO) PYRIMIDINE A ACTIVITE INHIBITRICE CDK
  申请人：ASTRAZENECA AB

  公开号：WO2003076436A1

  公开（公告）日：2003-09-18

  Compounds of the formula (I): wherein R1, R2, R3, R4, R5 and p are as defined within and a pharmaceutically acceptable salts and in vivo hydrolysable esters are described. Also described are processes for their preparation and their use as medicaments, particularly medicaments for producing a cell cycle inhibitory (anti-cell-proliferation) effect in a warm-blooded animal, such as man.

  公式（I）的化合物：其中R1、R2、R3、R4、R5和p的定义如下，并且描述了药学上可接受的盐和体内可水解酯。还描述了它们的制备过程以及它们作为药物的用途，特别是作为用于在温血动物（如人）中产生细胞周期抑制（抗细胞增殖）效果的药物。
• [EN] 4- IMIDAZOLYL SUBSTUITED PYRIMIDINE DERIVATIVES WITH CDK INHIBITIORY ACTIVITY<br/>[FR] DERIVES DE LA PYRIMIDINE SUBSTITUEE PAR 4-IMIDAZOLYLE PRESENTANT UNE ACTIVITE D'INHIBITION DE CDK
  申请人：ASTRAZENECA AB

  公开号：WO2003076434A1

  公开（公告）日：2003-09-18

  Compounds of the formula (I): wherein R1, R2, R3, R4, R5 and p are as defined within and a pharmaceutically acceptable salts and in vivo hydrolysable esters are described. Also described are processes for their preparation and their use as medicaments, particularly medicaments for producing a cell cycle inhibitory (anti-cell-proliferation) effect in a warm-blooded animal, such as man.

  公式（I）的化合物：其中R1、R2、R3、R4、R5和p的定义如内所述，并描述了一种药学上可接受的盐和体内可水解酯。还描述了它们的制备过程以及它们作为药物的用途，特别是用于在温血动物（如人）中产生细胞周期抑制（抗细胞增殖）效应的药物。
• Derivatives of 4-(imidazol-5-yl)-2-(4-sulfoanilino)pyrimidine with cdk inhibitory activity
  申请人：Newcombe John Nicholas

  公开号：US20050131000A1

  公开（公告）日：2005-06-16

  Compounds of the formula (I): wherein R 1 , R 2 , R 3 , R 4 , R 5 and p are as defined within and a pharmaceutically acceptable salts and in vivo hydrolysable esters are described. Also described are processes for their preparation and their use as medicaments, particularly medicaments for producing a cell cycle inhibitory (anti-cell-proliferation) effect in a warm-blooded animal, such as man.

  本文描述了化学式（I）的化合物，其中R1、R2、R3、R4、R5和p的定义如本文中所述，并描述了其药物学上可接受的盐和体内可水解的酯。同时还描述了它们的制备过程以及它们作为药物的用途，特别是作为产生对温血动物（如人）的细胞周期抑制（抗细胞增殖）效应的药物。
• 4-Imidazolyl substituted pyrimidine derivatives with cdk inhibitory activity
  申请人：Newcombe John Nicholas

  公开号：US20060074096A1

  公开（公告）日：2006-04-06

  Compounds of the formula (I): wherein R 1 , R 2 , R 3 , R 4 , R 5 and p are as defined within and a pharmaceutically acceptable salts and in vivo hydrolysable esters are described. Also described are processes for their preparation and their use as medicaments, particularly medicaments for producing a cell cycle inhibitory (anti-cell-proliferation) effect in a warm-blooded animal, such as man.

  本文描述了式(I)的化合物，其中R1、R2、R3、R4、R5和p的定义如文中所述，并描述了其药学上可接受的盐和体内可水解的酯。还描述了它们的制备过程以及它们作为药物的用途，特别是作为产生细胞周期抑制（抗细胞增殖）效应的药物，用于温血动物，如人类。
• 4-imidazolyl substituted pyrimidine derivatives with CDK inhibitory activity
  申请人：AstraZeneca AB

  公开号：US07442697B2

  公开（公告）日：2008-10-28

  Compounds of the formula (I): wherein R1, R2, R3, R4, R5 and p are as defined within and a pharmaceutically acceptable salts and in vivo hydrolysable esters are described. Also described are processes for their preparation and their use as medicaments, particularly medicaments for producing a cell cycle inhibitory (anti-cell-proliferation) effect in a warm-blooded animal, such as man.

  化合物的公式（I）：其中R1，R2，R3，R4，R5和p的定义如文中所述，并描述了药学上可接受的盐和体内可水解酯。还描述了它们的制备过程以及它们作为药物的用途，特别是用于在温血动物（例如人）中产生细胞周期抑制（抗细胞增殖）效应的药物。